Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

480 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference.
Atkins MB, Ernstoff MS, Figlin RA, Flaherty KT, George DJ, Kaelin WG Jr, Kwon ED, Libermann TA, Linehan WM, McDermott DF, Ochoa AC, Pantuck AJ, Rini BI, Rosen MA, Sosman JA, Sukhatme VP, Vieweg JW, Wood CG, King L. Atkins MB, et al. Among authors: flaherty kt. Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):667s-670s. doi: 10.1158/1078-0432.CCR-06-2231. Clin Cancer Res. 2007. PMID: 17255291 Review.
Phase I trial of combretastatin a-4 phosphate with carboplatin.
Bilenker JH, Flaherty KT, Rosen M, Davis L, Gallagher M, Stevenson JP, Sun W, Vaughn D, Giantonio B, Zimmer R, Schnall M, O'Dwyer PJ. Bilenker JH, et al. Among authors: flaherty kt. Clin Cancer Res. 2005 Feb 15;11(4):1527-33. doi: 10.1158/1078-0432.CCR-04-1434. Clin Cancer Res. 2005. PMID: 15746056 Clinical Trial.
Innovations and challenges in melanoma: summary statement from the first Cambridge conference.
Atkins MB, Elder DE, Essner R, Flaherty KT, Gajewski TF, Haluska FG, Hwu P, Keilholz U, Kirkwood JM, Mier JW, Ross MI, Slingluff CL, Sondak VK, Sosman JA, Weinstock MA, King L. Atkins MB, et al. Among authors: flaherty kt. Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2291s-2296s. doi: 10.1158/1078-0432.CCR-05-2560. Clin Cancer Res. 2006. PMID: 16609047
Inhibition of mutated, activated BRAF in metastatic melanoma.
Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB. Flaherty KT, et al. N Engl J Med. 2010 Aug 26;363(9):809-19. doi: 10.1056/NEJMoa1002011. N Engl J Med. 2010. PMID: 20818844 Free PMC article. Clinical Trial.
Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma.
McArthur GA, Puzanov I, Amaravadi R, Ribas A, Chapman P, Kim KB, Sosman JA, Lee RJ, Nolop K, Flaherty KT, Callahan J, Hicks RJ. McArthur GA, et al. Among authors: flaherty kt. J Clin Oncol. 2012 May 10;30(14):1628-34. doi: 10.1200/JCO.2011.39.1938. Epub 2012 Mar 26. J Clin Oncol. 2012. PMID: 22454415 Free PMC article. Clinical Trial.
Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy.
Cho DC, Hutson TE, Samlowski W, Sportelli P, Somer B, Richards P, Sosman JA, Puzanov I, Michaelson MD, Flaherty KT, Figlin RA, Vogelzang NJ. Cho DC, et al. Among authors: flaherty kt. Cancer. 2012 Dec 15;118(24):6055-62. doi: 10.1002/cncr.27668. Epub 2012 Jun 6. Cancer. 2012. PMID: 22674198 Free PMC article. Clinical Trial.
480 results